News

Caretaker Medical Chosen as Finalist to Compete for $350,000 Grand Prize at MedTech Conference

This year brought in a record number of applications with over 1,100 submissions from 54 countries and 42 U.S. states. With less than a 5% acceptance rate, 50 companies were selected to participate in the MedTech Innovator Showcase, with a subset receiving a place in the MedTech Innovator Accelerator. Over four months, 25 Accelerator companies competed for a coveted spot in the Grand Finals. The five finalists are developing medical technology innovations in remote monitoring, patient safety and satisfaction, and prevention:

  • Alva Health (New Haven, CT) is developing a real-time, wearable stroke monitor for older Americans living with high stroke risk.
  • BioDevek (Brookline, MA) is developing an endoscopically-sprayable adhesive hydrogel to seal and protect surgical lesions after polyp removal.
  • Caretaker Medical (Charlottesville, VA ) is developing a wireless finger sensor for continuous “beat by beat” blood pressure and hemodynamics remote monitoring.
  • Cooler Heads Care (San Diego, CA) is developing an affordable wearable device so chemo patients can keep their hair.
  • Nutromics (Brunswick, AUS) is developing a wearable continuous molecular monitoring platform that can track drugs, hormones, metabolites, and proteins.

The final competition will be both live in-person as well as livestreamed on Wednesday, Sept. 29 at 12:00 PM ET during the The MedTech Conference. Viewers will vote online and in-person to decide who takes home the $350,000 Grand Prize and title of MedTech Innovator 2021. Register to watch the competition livestream here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business